In the News ORGANOPlus Exhibits Human Validation Platform at BIO KOREA 2026 Apr 29, 2026 ORGANOPlus exhibited its human-relevant validation platform at BIO KOREA 2026.The company highlighted CANORGAN™ for tumor microenvironment-based immuno-oncology validation and VILLIORGAN™ for microbiome-related mechanism discovery.The platform supports preclinical decision-making with more predictive human-based data. PreviousAACR 2026 Highlights the Shift Toward Human-Relevant Platforms in Cancer ResearchNextCPHI South East Asia 2026: ORGANOPlus Showcases Proprietary Probiotic Strain OP820 Back to list
